EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical trials in branch retinal vein occlusion

Tandava Krishnan Panakanti, Jay Chhablani

Middle East African Journal of Ophthalmology · 2016 · 23 (1) · 38

DOI: 10.4103/0974-9233.172294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Middle East African Journal of Ophthalmology, 2016. Verfasst von Tandava Krishnan Panakanti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vitreo-retina Consultant, Vasan Eye Care, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Branch retinal vein occlusion (BRVO) is the second most common retinal vascular disorder. The management of macular edema has changed considerably over time. The laser is considered the gold standard treatment for over two decades. However, visual recovery with laser is usually slow and incomplete. The advent of intravitreal agents, specifically anti-vascular endothelial growth factors (VEGF) have heralded a new era which promises rapid recovery of vision and quality of vision. Randomized clinical trials have reported optimal results with anti-VEGF agents (ranibizumab, bevacizumab, and aflibercept) compared to laser therapy or steroids. However, nearly 50% of the patients require repeat intravitreal anti-VEGF therapy up to 4 years after initiating therapy to sustain the visual gains. The adverse events (systemic and ocular) of these agents are minimal. Monotherapy with anti-VEGF agents have been found to provide better results than any combination with laser. This review article summarizes evidence from randomized controlled trials evaluating treatment options for the treatment of macular edema secondary to BRVO with a special focus on anti-VEGF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsMacular EdemaRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionVascular Endothelial Growth Factor AVisual Acuity

Stichwörter der Autor:innen

Anti-Vascular Endothelial Growth FactorsBranch Retinal Vein OcclusionClinical TrialsMacular Edema

Substanzen

Angiogenesis InhibitorsRecombinant Fusion ProteinsVEGFA protein, humanVascular Endothelial Growth Factor AafliberceptBevacizumabReceptors, Vascular Endothelial Growth FactorRanibizumab

Autor:innen und Institutionen

  • Vitreo-retina Consultant, Vasan Eye Care, Hyderabad, Telangana, India.
  • Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Eye Institute, Hyderabad, Telangana, India.

Zitieren

APA

Panakanti, T. K., & Chhablani, J. (2016). Clinical trials in branch retinal vein occlusion. Middle East African Journal of Ophthalmology, 23(1), 38. https://doi.org/10.4103/0974-9233.172294

Vancouver

Panakanti TK, Chhablani J. Clinical trials in branch retinal vein occlusion. Middle East African Journal of Ophthalmology. 2016;23(1):38. doi:10.4103/0974-9233.172294

BibTeX
@article{Panakanti2016,
  author = {Panakanti, Tandava Krishnan and Chhablani, Jay},
  title = {Clinical trials in branch retinal vein occlusion},
  journal = {Middle East African Journal of Ophthalmology},
  year = {2016},
  volume = {23},
  number = {1},
  pages = {38},
  doi = {10.4103/0974-9233.172294}
}
Kostenlos starten →